Last reviewed · How we verify
IL28B Polymorphism
At a glance
| Generic name | IL28B Polymorphism |
|---|---|
| Sponsor | Dr.Waleed Samir |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
- Prevalence of IL28B Polymorphism in Hepatitis C Patients
- Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism (PHASE4)
- A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253 (PHASE3)
- A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B
- Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma (NA)
- Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients (PHASE4)
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL28B Polymorphism CI brief — competitive landscape report
- IL28B Polymorphism updates RSS · CI watch RSS
- Dr.Waleed Samir portfolio CI